Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Breast Cancer
•
Medical Oncology
•
Breast Cancer, Non-metastatic
Will you consider PD-L1 expression to estimate the likelihood of response to neoadjuvant chemotherapy in ER positive/HER-2 negative breast cancer after results of the Keynote-756?
Related Questions
Would you offer systemic therapy (TH) to a patient with HER2+ (3+), HR- high grade microinvasive breast cancer with single focus or multifocal?
Would you give KEYNOTE 522 in combination with trastuzumab/pertuzumab neoadjuvantly for multifocal disease?
Can you safely proceed with breast irradiation during treatment with immunotherapy?
How would you decide the duration of ovarian suppression in premenopausal females with early stage ER+ breast cancer?
For pre or perimenopausal women with early stage, hormone positive breast cancer who refuse to stop HRT (for severe perimenopausal symptoms - severe depression/anxiety/very low energy/vaginal dryness and pain with sex that's failed vaginal estrogen therapy), do you still recommend Tamoxifen or other endocrine therapy in addition to the HRT that is being taken?
What would you recommend regarding HRT use in a patient with history of HR-, HER2+ breast cancer dealing with post-menopausal symptoms?
What endocrine therapy would you recommend to a premenopausal female with early stage HR+ Breast cancer who is transitioning from female to male and currently on testosterone?
Would you give AC followed by Taxol or TC for luminal type B, clinical high risk, breast cancer?
Is there an increaed risk of cancer when using spironolactone in patients with hormone positive breast cancer?
In which scenarios do you use vaginal estrogen in patients with history of HR positive breast cancer?